All Type of News
Leading drug makers fared worse performances
The country’s top-tier companies have struggled to find their feet during the nine months of the year, after a government-mandated price cut came into effect in April.
According to data released by Yakup.com, a pha...
Biopid wins approval for atopic skin disease drug
A local biopharmaceutical company has won approval to produce a novel medicine for the topical treatment of atopic skin disease.
Biopid announced Tuesday that the Korea Food and Drug Administration approved its pro...
Iljin renames itself CosmaxBio
Iljin Pharmaceuticals said Tuesday that it will rename itself CosmaxBio from Nov. 12 in a bid to boost up its functional health business.
The previous name, Iljin Pharmaceuticals, has been in use since Cosmax, a co...
Domestic hyperlipidemia drug market in transition
The local hyperlipidemia drug market is undergoing a major transformation as Janssen’s Crestor (rosuvastatin)is likely to overtake Pfizer’s Lipitor (atorvastatin) in sales, reshuffling the leader board of a popular dr...
What’s on Teva’s mind?
Shares of the mid-tier pharmaceutical firms has been in steep rally, since a health ministry official said that generic drug giant Teva enters into an agreement with a Korean firm over possible merger.
So far, seve...
Janssen Korea’s associate wholesaler goes belly-up
Janssen Korea’ associate wholesaler located at Daerim-dong in Seoul went bankrupt amid spreading rumors that the bankruptcy is closely associated with a mutual agreement expired last month, market sources said on Octo...
Innovative drug firms are under probe over illegal kickbacks
The nation’s 43 innovative drug firms are under screening process over their history of illegal rebate, according to market sources.
The Ministry of Health and Welfare Monday delivered a circular letter to those su...
Daehan New Pharm to supply 60 billion won protein A
Daehan New Pharm said Monday that has established a a marketing and distribution partnership with the U.S. based GenScript and Japan based Pharmawin to supply protein A worth 60 billion won.
The capacity of protein...
Teva’s merger is still in fog
There are spreading rumors that Israel generic giant Teva would acquire majority stocks of a Korean mid-sized pharmaceutical firm worth 100 billion won, but the details are yet unidentified.
Several companies, incl...
Celltrion opens world-first biosimilar symposium
Celltrion, a local biopharmaceutical company, said Friday it held a launching symposium for its world’s first antibody biosimilar ‘Remsima’ at Millennium Hilton Hotel in Seoul.
Remsima is a biosimilar version of U....
